Kyverna Therapeutics Strengthens Board With New Director Appointments

The latest announcement is out from Kyverna Therapeutics, Inc. ( (KYTX) ).

On February 24, 2026, Kyverna Therapeutics appointed biopharma veteran Andrew Miller, Ph.D., as a Class III director, adding him to its Science and Technology and Audit committees and granting him cash retainers and equity awards aligned with its non-employee director program. Miller, founder and former R&D president of Karuna Therapeutics, brings deep drug development expertise and a history of value creation, including Karuna’s $14 billion sale to Bristol Myers Squibb and the approval of schizophrenia drug COBENFY.

The same day, Kyverna named Beam Therapeutics CFO Sravan Emany as a Class I director and chair of the Audit Committee, also placing him on the Nominating and Corporate Governance Committee with corresponding cash and equity compensation. Emany’s capital markets and M&A experience, together with Miller’s clinical and operational track record, are expected to strengthen Kyverna’s board as it advances autoimmune CAR T programs and nears commercialization, while replacing outgoing director and former audit chair Daniel Spiegelman, who resigned effective February 24, 2026 without any reported disagreements.

The most recent analyst rating on (KYTX) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.

Spark’s Take on KYTX Stock

According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.

The score is held back primarily by weak financial performance (no revenue, widening losses, and rising cash burn), partially offset by low leverage. Corporate events are a meaningful positive (clinical data, funding, and leadership/manufacturing build-out), while technicals are mixed and valuation metrics provide limited support due to negative earnings and no dividend.

To see Spark’s full report on KYTX stock, click here.

More about Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases. Its lead autologous CD19-targeting CAR T-cell candidate, miv-cel (KYV-101), underpins a potentially first-in-class neuroimmunology franchise spanning stiff person syndrome, generalized myasthenia gravis, multiple sclerosis, rheumatoid arthritis and other B-cell-driven autoimmune conditions.

The company is building a next-generation pipeline of CAR T-cell therapies designed to improve patient access and treatment experience. Headquartered in Emeryville, Calif., Kyverna is positioning itself toward commercialization as it advances registrational trials and broader KYSA and investigator-initiated studies in autoimmune indications.

Average Trading Volume: 1,474,587

Technical Sentiment Signal: Buy

Current Market Cap: $438.8M

For detailed information about KYTX stock, go to TipRanks’ Stock Analysis page.